Case report · 3 May 2019
Case reportPublished 26 Aug 2019
Pulmonary tuberculosis treated with
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Every year, 220,000 new cases of tuberculosis are registered in the Americas, and more than 50,000 die as a result of this disease. It is worth noting that tuberculosis is both preventable and curable, however, it still is one of the most important transmitted infections in the world. Multiple factors explain this situation, one of them being the lack of commitment to treatment, due to the number of pills the patient must take and the side effects they may have. This raises the necessity of developing an efficient therapy that decreases negative side effects and permits proper adherence to the treatment. To this day there is no registered use of “Onnetsu” far infrared rays on patients suffering from tuberculosis. Take the case of a 67 year-old woman diagnosed with pulmonary tuberculosis (TB) based on clinical, radiological and bacteriological evidence, for which she was admitted in the National Health Strategy for the Prevention and Control of Tuberculosis (ESNPCT) and was receiving pharmacological treatment for 1 month (Rifampicin 300 mg, Ethambutol 400 mg, Isoniazid 100 mg, Pyrazinamide 500 mg), which she abandoned when she began having adverse reactions (nausea, vomiting, loss of appetite, weakness and dyspepsia). Due to this situation she went to the Traditional Medical Institute-IMET ESSALUD, where the diagnosis of pulmonary tuberculosis was confirmed and then signed an informed consent form where she agreed to receive “Onnetsu” far infrared ray treatment, which was applied to the skin, focusing on the thorax, done in one hour sessions, 3 times per week for 18 weeks, during which she received no pharmacological treatment. At the end of the treatment, betterment in both the clinical and radiological pictures and an adequate bacteriological response resulted in her being discharged from ESNPCT. Monitoring was done over the next 6 years y no evidence of active TB was found. This report could be the first step in opening the studies on the use of far infrared rays as a potential treatment for pulmonary tuberculosis.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 2017
Rifampicin-Versus Ethambutol-Based Continuation Phase Anti Tuberculosis Treatment Regimen is among Factors Associated with Treatment Outcomes in Patients Treated at Six Health Facilities in Southern Ethiopia
Brief report · 31 Mar 2025
Unusual Presentation of Pulmonary Tuberculosis Mimicking Lung Carcinoma: A Case Report
Article · 2025
Imaging Tuberculosis and Pulmonary Infections: A Visual Atlas
Short communication · 20 Feb 2023
Patients with Freshly Discovered Pulmonary Tuberculosis May Experience Haematological Symptoms
More from this journal
The newest in Clinical Investigation.
Article · 30 Apr 2025
Vaccine Clinical Trials: Ensuring Safety, Immunity, and Public Health Protection
Article · 30 Apr 2025
Safety and Toxicity Assessment in Clinical Research: Ensuring Patient Protection and Drug Reliability
Article · 30 Apr 2025
Regulatory Compliance (FDA, EMA, CDSCO) in Drug Efficacy Studies: Ensuring Global Standards in Clinical Research
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Aranda-Ventura Jose”
- BylineArticles whose byline prints “Tatsumura-Hillyer Kazuko”
